In Conversation

NIH's Carl Dieffenbach on the Long Road to a HIV Vaccine

NIH's Carl Dieffenbach on the Long Road to a HIV Vaccine

My goal has been to try to develop strategies and approaches that – when implemented at scale – could really have an impact on HIV incidence
Guy Jean Savoir – CEO, Carnot Laboratories

Guy Jean Savoir – CEO, Carnot Laboratories

The involvement of private entities has proven extremely beneficial, contributing to growth and market stability. However, despite these successes, there remains a widespread sentiment within the industry for greater transparency and organization in government dealings.  
Koji Ueda – Managing Director, Otsuka Pharmaceutical Hong Kong

Koji Ueda – Managing Director, Otsuka Pharmaceutical Hong Kong

CNS is a crucial portfolio segment for us, both globally and in Hong Kong. We can proudly say that we are one of the leading companies in the Hong Kong CNS market in terms of sales volume and market share  
Lionel Collet – President, Haute Autorité de Santé (HAS), France

Lionel Collet – President, Haute Autorité de Santé (HAS), France

Maintaining independence is paramount because we must never be beholden, in any way, to either industry interests or governmental influence.
Ahmad Hersi – CEO, King Saud University Medical City

Ahmad Hersi – CEO, King Saud University Medical City

These international collaborations are in alignment with the new vision set forth for KSUMC, which strives to rank among the top 10 universities and medical centers globally.
João Filipe Raposo – Clinical Director, APDP – Diabetes Portugal

João Filipe Raposo – Clinical Director, APDP – Diabetes Portugal

I am optimistic that diabetes care will improve. The inequality of care in Europe and Portugal exists, and it is really important to plan how we get the most innovative treatments to the most patients
Yu Wang – Chairman, Chinese Foundation for Hepatitis Prevention & Control

Yu Wang – Chairman, Chinese Foundation for Hepatitis Prevention & Control

The regulatory environment in China, guided by the NMPA, appears to be evolving positively, providing a conducive framework for pharmaceutical innovation and growth
Access to Medicine Foundation CEO on HIV Access Trends

Access to Medicine Foundation CEO on HIV Access Trends

We can't afford to have companies withdraw from infectious disease research—it's crucial for global health security
Sanjay Bhutani – Country Manager, Bausch & Lomb India

Sanjay Bhutani – Country Manager, Bausch & Lomb India

India is a market with great potential. However, it's important to recognize that the market is price-sensitive, requiring patience and a strategic approach
See more

In Case You Missed It

InFigures

The subject of intense industry criticism from the likes of lobby groups, Big Pharma, and biotech alike, the Inflation Reduction Act (IRA) subjects certain drugs to price negotiations directly with industry sponsors in the US for the first time. Ten initial drugs – which accounted for over USD 45 billion in Medicare Part D spending…

After the Hong Kong Exchanges and Clearing Limited’s (HKEX) 2018 move to allow pre-revenue biotech companies to raise capital in Hong Kong under its Chapter 18A mechanism, biotech listings surged with pre-clinical companies chosing to list on HKEX as a means of accessing global capital, raising around HKD 118 billion in funding. After a record…

The top 10 Indian pharma companies ranked by market capitalization as of June 2023, compiled by Global Data. Way out in front is Sun Pharma, followed by Dr Reddy’s and Cipla. Made with Visme Infographic Maker

Latin America will be the world’s fastest growing region for pharmaceuticals up to 2027, with a stunning expected compound annual growth rate of 22 percent, according to recent reporting from IQVIA. The Indian subcontinent can also expect sizeable growth over the next three years, although the US, Europe, and East Asia will remain the largest…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here